Newsfeeds Archive - Page 3 of 6

2 minute read

FDA Removes Clinical Hold Of Pharvaris’ Deucrictibant For On-Demand Treatment Of HAE

June 26, 12:27 PM

Pharvaris NV (NASDAQ: PHVS) announced that the FDA lifted the clinical hold on the Investigational New Drug (IND) application for deucrictibant (PHA-121) for the on-demand

PHVS

2 minute read

Analyst Ratings

What 4 Analyst Ratings Have To Say About Pharvaris

By Benzinga Insights

April 6, 12:00 PM

Within the last quarter, Pharvaris (NASDAQ:PHVS) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

PHVS

2 minute read

Pharvaris Phase 2 Data From RAPIDe-1 Study Of PHVS416 For The On-Demand Treatment Of Hereditary Angioedema Attacks Highlighted At The 2023 HAEi Regional Conference APAC On Saturday, March 18

By Happy Mohamed

March 18, 1:46 AM

Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced an oral presentation of positive

PHVS

1 minute read

JMP Securities Reiterates Market Outperform on Pharvaris, Maintains $23 Price Target

By Benzinga Newsdesk

February 27, 9:26 AM

JMP Securities analyst Jonathan Wolleben reiterates Pharvaris (NASDAQ:PHVS) with a Market Outperform and maintains $23 price target.

PHVS

1 minute read

SVB Leerink Maintains Outperform on Pharvaris, Lowers Price Target to $18

By Benzinga Newsdesk

February 3, 7:38 AM

SVB Leerink analyst Joseph Schwartz maintains Pharvaris (NASDAQ:PHVS) with a Outperform and lowers the price target from $20 to $18.

PHVS

1 minute read

Catalyst Pharmaceuticals, Xylem And Other Big Stocks Moving Lower On Monday

By Lisa Levin

January 23, 12:36 PM

U.S. stocks traded higher, with the Dow Jones gaining over 300 points on Monday. Here are some big stocks recording losses in today’s session.

ANPC

1 minute read

CommVault Systems, Halozyme Therapeutics And Other Big Stocks Moving Lower On Wednesday

By Lisa Levin

January 11, 12:30 PM

U.S. stocks traded higher, with the Dow Jones gaining around 80 points on Wednesday. Here are some big stocks recording losses in today’s session.

CVAC

1 minute read

JMP Securities Maintains Market Outperform on Pharvaris, Raises Price Target to $23

By Benzinga Newsdesk

January 11, 9:38 AM

JMP Securities analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and raises the price target from $22 to $23.

PHVS

4 minute read

EXCLUSIVE: Top 10 Searched Tickers On Benzinga Pro In December 2022: Where Do Tesla, Apple, AMC Rank?

By Chris Katje

January 3, 7:54 PM

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

AAPL

4 minute read

Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

December 28, 2:00 PM

Gainers Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal epithelial defect.

$APE